Applied Filters
What drives the urge to merge?
There is some debate about whether the ‘patent cliff’ or the need to innovate is driving M&A activity in the pharmaceutical industry, where billions of dollars have been spent in the past few years, as LSIPR finds out.
LSIPR 50 2016: Chunli Bai and Kyle Bass
Chunli Bai and Kyle Bass were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Bai and Bass were featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2016: Jorge Kalil and Narendra Modi
Jorge Kalil and Narendra Modi were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Kalil and Modi were featured in the government and policy section, as LSIPR reports.
LSIPR 50 2016: Jarbas Barbosa da Silva Jr and Margaret Chan
Jarbas Barbosa da Silva Jr and Margaret Chan were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Love featured in the government and policy section, as LSIPR reports.
LSIPR 50 2016: Xi Jinping and George Freeman
Xi Jinping and George Freeman were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Jinping and Freeman were featured in the government and policy section, as LSIPR reports.
A bright future for biologics in Thailand
An increasing number of biologics and biosimilar products are appearing in the Thai market, but there are challenges concerning IP protection and regulation, say Alan Adcock and Atthachai Homhuan of Tilleke & Gibbins.
Easing the path for green tech in India
Even if India moves towards a patent-unfriendly environment for green technologies, the pro-patent and pro-environment lobbies can coexist and meet their respective goals, argue Swarup Kumar and Jitesh Kumar of Remfry & Sagar.
China v US: what can be patented in the life sciences field?
The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports.
Running an efficient clinical drug trial
Everyone benefits from an efficiently run clinical drug study, including sponsors, contract research organisations, the investigator sites where patients are treated and observed, and most of all, patients, says Charlie Nicholson of Premier Research.
Case report: Biocon’s breast cancer biosimilar gets green light
In a recent decision in India, biopharma company Biocon and its partner Mylan were allowed to continue marketing a biosimilar breast cancer drug, as Vikrant Rana and Sanjeeta Das of SS Rana report.
